Evaluation of optimal 5ASA dose in order to determine for keeping remission of patients with ulcerative colitis by colonoscopy using FICE (flexible spectral imaging color enhancement) system.
Not Applicable
- Conditions
- lcerative colitis
- Registration Number
- JPRN-UMIN000005270
- Lead Sponsor
- Saitama Medical Center, Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who cannot accept colonoscopy Patients who have no agreement of this study Patients who is pregnant or possibly be pregnant Patients who had operation of total or partial colectomy Patients who got to start to take treamtents such as; -sterids (intravenous, peroral, enema and suppo) within 4 weeks -metrinidazole within 4 weeks -infliximab within 4 weeks -elemental diet or IVH within 4 weeks -cyclosporine or tacrolimus within 4 weeks -azathiopurine or 6MP within 4 weeks -mesalazine enema or suppo within 4 weeks -increase or decrease the mesalazine dose within 4 weeks
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method non-relapse rate by CAI score after one year
- Secondary Outcome Measures
Name Time Method clinical Activity Index (CAI) vascular grading (VG) vascular score (VS) non-relapse rate after 3,6,9 months inflammatory response score(WBC, Plt, ESR, CRP) pathological Matts gradings safety remission period (month)